S'abonner

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders - 05/04/23

Doi : 10.1016/j.jaci.2022.11.013 
Kai M.T. Sauerwein, MSc a, b, c, Christoph B. Geier, MD a, Roman F. Stemberger, MSc a, Raphael Rossmanith, MSc a, Hüseyin Akyaman, BSc a, Peter Illes, MD d, Michael B. Fischer, MD c, e, Martha M. Eibl, MD a, b, Jolan E. Walter, MD f, g, Hermann M. Wolf, MD a, h,
a Immunology Outpatient Clinic, Vienna, Austria 
b Biomedizinische Forschung & Bio-Produkte AG, Vienna, Austria 
c Department for Biomedical Research, Center of Experimental Medicine, Danube University Krems, Krems an der Donau, Austria 
d USF Health Department of Pediatrics, Division of Allergy/Immunology, Children’s Research Institute, St Petersburg, Fla 
e Clinic for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria 
f Division of Allergy and Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, Fla 
g Division of Allergy/Immunology, Department of Pediatrics, Johns Hopkins All Children’s Hospital, St Petersburg, Fla 
h Sigmund Freud Private University, Medical School, Vienna, Austria 

Corresponding author: Hermann M. Wolf, MD, Immunology Outpatient Clinic, Schwarzspanierstraße 15, 1090 Vienna, Austria.mmunology Outpatient ClinicISchwarzspanierstraße 15Vienna1090Austria

Abstract

Background

Although previous studies described the production of IgG antibodies in a subgroup of patients with common variable immunodeficiency (CVID) following messenger RNA vaccinations with BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (CVID responders), the functionality of these antibodies in terms of avidity as measured by the dissociation rate constant (kdis) and the antibody response to booster immunization has not been studied.

Objective

We sought to analyze in CVID responders and healthy individuals, the avidity of anti–SARS-CoV-2 serum antibodies and their neutralization capacity as measured by surrogate virus–neutralizing antibodies in addition to IgG-, IgM-, and IgA-antibody levels and the response of circulating (peripheral blood) follicular T-helper cells after a third vaccination with BNT162b2 SARS-CoV-2 messenger RNA vaccine.

Methods

Binding IgG, IgA, and IgM serum levels were analyzed by ELISA in patients with CVID responding to the primary vaccination (CVID responders, n = 10) and healthy controls (n = 41). The binding avidity of anti–spike antibodies was investigated using biolayer interferometry in combination with biotin-labeled receptor-binding-domain of SARS-CoV-2 spike protein and streptavidin-labeled sensors. Antigen-specific recall T-cell responses were assessed by measuring activation-induced markers by flow cytometry.

Results

After the third vaccination with BNT162b2, IgG-, IgM-, and IgA-antibody levels, surrogate virus–neutralizing antibody levels, and antibody avidity were lower in CVID responders than in healthy controls. In contrast, anti–SARS-CoV-2 spike protein avidity was comparable in CVID responders and healthy individuals following primary vaccination. Follicular T-helper cell response to booster vaccination in CVID responders was significantly reduced when compared with that in healthy individuals.

Conclusions

Impaired affinity maturation during booster response provides new insight into CVID pathophysiology.

Le texte complet de cet article est disponible en PDF.

Key words : BNT162b2 booster vaccination, CVID, antibody avidity, cTfh, biolayer interferometry

Abbreviations used : αSpike, cTfh, CVID, CVID R, HC, IQR, IVIG, kdis, SARS-CoV-2, sVNT


Plan


 This study was supported by the Österreichische Forschungsförderungsgesellschaft mbH (grant no. 881639), and by the Jeffrey Modell Foundation, the Johns Hopkins Research Foundation, and the Robert A. Good Endowment.
 Ethics statement: The study was conducted in accordance with the Declaration of Helsinki and fulfils the guidelines of the Austrian Agency of Research Integrity (OeAWI). With respect to the patient analyses, this study was approved by the Ethics Committee of the Immunology Outpatient Clinic as a study using the biobank of residual specimen of the Immunology Outpatient Clinic. According to the Ethics Committee of the City of Vienna and the legal regulations to be applied (§15a Abs. 3a Wiener Krankenanstaltengesetz), no additional ethics committee evaluation is required for a noninterventional study using data and material collected as part of the routine medical care the patients received. The patients gave their informed consent that anonymized data collected as part of the routine medical attendance (serum antibody measurements and T-cell activation assays) could be included in a scientific publication. All patient information in this study is anonymized and deidentified. No extra intervention was carried out.
 Disclosure of potential conflict of interest: K. M. T. Sauerwein and M. M. Eibl were employed by the company Biomedizinische Forschung & Bio-Produkte AG, which had no role in the design of this study or during its execution, and was not involved in the analyses, interpretation of the data, and the decision to submit the present manuscript for publication. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 151 - N° 4

P. 922-925 - avril 2023 Retour au numéro
Article précédent Article précédent
  • SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity
  • Marco Rosichini, Veronica Bordoni, Domenico Alessandro Silvestris, Davide Mariotti, Giulia Matusali, Antonella Cardinale, Giovanna Zambruno, Angelo Giuseppe Condorelli, Sara Flamini, Shirley Genah, Marialuigia Catanoso, Franca Del Nonno, Matteo Trezzi, Lorenzo Galletti, Cristiano De Stefanis, Nicolò Cicolani, Stefania Petrini, Concetta Quintarelli, Chiara Agrati, Franco Locatelli, Enrico Velardi
| Article suivant Article suivant
  • NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2–related complications
  • Aaron Bodansky, Sara E. Vazquez, Janet Chou, Tanya Novak, Amer Al-Musa, Cameron Young, Margaret Newhams, Suden Kucukak, Laura D. Zambrano, Anthea Mitchell, Chung-Yu Wang, Kristin Moffitt, Natasha B. Halasa, Laura L. Loftis, Stephanie P. Schwartz, Tracie C. Walker, Elizabeth H. Mack, Julie C. Fitzgerald, Shira J. Gertz, Courtney M. Rowan, Katherine Irby, Ronald C. Sanders, Michele Kong, Jennifer E. Schuster, Mary A. Staat, Matt S. Zinter, Natalie Z. Cvijanovich, Keiko M. Tarquinio, Bria M. Coates, Heidi R. Flori, Mary K. Dahmer, Hillary Crandall, Melissa L. Cullimore, Emily R. Levy, Brandon Chatani, Ryan Nofziger, Overcoming COVID-19 Network Study Group Investigators,, Raif S. Geha, Joseph DeRisi, Angela P. Campbell, Mark Anderson, Adrienne G. Randolph, Michele Kong, Ronald C. Sanders, Masson Yates, Chelsea Smith, Natalie Z. Cvijanovich, MattS. Zinter, Gwenn McLaughlin, Keiko M. Tarquinio, Bria M. Coates, Courtney M. Rowan, Adrienne G. Randolph, Margaret M. Newhams, Suden Kucukak, Tanya Novak, Hye Kyung Moon, Takuma Kobayashi, Jeni Melo, Cameron Young, Sabrina R. Chen, Janet Chou, Heidi R. Flori, Mary K. Dahmer, Emily R. Levy, Supriya Behl, Noelle M. Drapeau, Jennifer E. Schuster, Melissa L. Cullimore, Russell J. McCulloh, Shira J. Gertz, Stephanie P. Schwartz, Tracie C. Walker, Ryan A. Nofziger, Mary Allen Staat, Chelsea C. Rohlfs, Julie C. Fitzgerald, Elizabeth H. Mack, Nelson Reed, Natasha B. Halasa, Laura L. Loftis, Hillary Crandall

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.